

Gastric Cancer

abstr 0847

Treatment Outcomes of Oxaliplatin, 5-Fluorouracil, and Leucovorin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer: A Retrospective Analysis

Yeul Hong Kim, Hee Yeon Seo, Dae Sik Kim, Yoon Seok Choi, Hwa Jung Sung, Kyong Hwa Park, In Keun Choi, Seok Jin Kim, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Jun Suk Kim

Division of Oncology-Hematology, Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea

Background: We performed a single-institution retrospective study to evaluate the efficacy and toxicities of oxaliplatin, 5-fluorouracil (5-FU), leucovorin (LV) combination chemotherapy as salvage treatment in patients with metastatic or advanced gastric cancer.

Methods: Sixty-two (62) patients with advanced gastric cancer previously treated were eligible for the study. Patients received oxaliplatin 100 mg/m² and LV 100 mg/m² (2-hour intravenous infusion) followed by 5-FU 2,400 mg/m² (46-hour continuous infusion) every 2 weeks, and responses were assessed after every 3 cycles.

Results: Fifty-nine (59) out of 62 patients were assessable for response. Among them, 46 patients had previously been treated with cisplatin-based chemotherapy. Patients had a median age of 57 years (range, 32 to 76 years); 72.6% had an Eastern Cooperative Oncology Group performance status of 0 or 1. A total 296 courses of chemotherapy were administered as second-line (67.7%) or third-line (27.4%) treatment, and the median number of courses per patient was 3. Out of 59 evaluable patients, 14 partial responses

were observed (overall response rate, 22.6%). Stable disease was observed in 22 patients (35.5%), and progressive disease in 23 patients (37.1%). The median response duration, time to progression, and overall survival were 2.3 months, 3.0 months, and 8.0 months, respectively. The major toxicities were neutropenia, mucositis, and peripheral neuropathy. Grade 3 or 4 hematologic toxicities included neutropenia in 9 patients (14.5%) and thrombocytopenia in 1 patient (1.6%). Other grade 3 or 4 toxicities included mucositis in 1 patient (1.6%) and vomiting in 2 patients (3.2%). Grade 1 or 2 peripheral neuropathy was observed in 18 patients (29.1%), however, there were no cases of grade 3 or 4 peripheral neuropathy and no treatment-related deaths.

Conclusion: The combination of oxaliplatin, 5-FU, and LV was effective and safe salvage chemotherapy in advanced gastric cancer patients.